World Library  
Flag as Inappropriate
Email this Article

HPV-positive oropharyngeal cancer

Article Id: WHEBN0024795530
Reproduction Date:

Title: HPV-positive oropharyngeal cancer  
Author: World Heritage Encyclopedia
Language: English
Subject: Papillomavirus, Human papillomavirus, Heck's disease, Arbovirus encephalitis, Central nervous system viral disease
Publisher: World Heritage Encyclopedia

HPV-positive oropharyngeal cancer

HPV-positive oropharyngeal cancer
Classification and external resources
HPV positive HNSCC (in situ hybridization)
ICD-10 C09.0-C10.9

Human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) also known as HPV16+ oropharyngeal cancer or HPV+ OPC is a recognized subtype of Oropharyngeal squamous cell carcinomas (OSCC),[1][2][3] associated with the HPV type 16 virus.


HPV oral infection precedes the development of HPV+ OPC.[4][5] Slight injuries in the mucous membrane serve as an entry gate for HPV, which thus works into the basal layer of the epithelium.[6][7] People testing positive for HPV16 oral infection have a 14 times increased risk of developing HPV+ OPC.[6]

Immunosuppression seems to be an increased risk factor for HPV+ OPC.[5] Individuals with TGF-β1 genetic variations, specially T869C, are more likely to have HPV16+ OPC.[8] TGF-β1 plays an important role in controlling the immune system.

A 1999 study has found that patients with human papillomavirus (HPV)-associated anogenital cancers had a 4.3-fold increased risk of tonsillar squamous-cell carcinoma.[9]

Although evidence suggests that HPV16 is the main cause of OPC between non-smokers and non-drinkers, the degree to which tobacco and/or alcohol use may contribute to increase the risk of HPV+ OPC is unclear.[5] Concomitant human herpesvirus-8 infection can potentiate the effects of HPV-16.[10]


A prospective study has found that increased HPV+ OPC risk was observed more than 15 years after HPV exposure,[4] pointing to a slow development of the disease, like in cervical cancer.

HPV associated cancers are caused by the expression of HPV's E6 and E7 proteins that bind to and inactivate tumor suppressor proteins p53 and retinoblastoma protein (pRB), respectively, leading to malignant transformation of HPV infected cells.[4][11]

The biology of HPV+ OPC is distinct of HPV- OPC with P53 degradation (inactivated by E6 instead of by genetic mutation), pRB pathway inactivation (by E7 instead of Cyclin D1 amplification), and P16 upregulation (over-expression of p16 instead of inactivation due to reduced negative feedback from pRB).[12][13]

The tonsils epithelia (palatine and lingual) share similar nonkeratinization characteristics with the cervix, where HPV infection play the major role in cases of cervical cancer.[6][14]


HPV+ OPC is usually diagnosed at a more advanced stage than HPV- OPC.[4]

Genetic signatures of HPV+ and HPV- OPC are different.[15][16][17][18][19]

HPV OPC is associated with expression level of the E6/E7 mRNAs and of p16.[20] Nonkeratinizing squamous cell carcinoma strongly predicts HPV-association.[21][22]

HPV OPC is not merely characterized by the presence of HPV-16. Only the expression of viral oncogenes within the tumor cells plus the serum presence of E6 or E7 antibodies is unambiguously conclusive.[6]

There's not a standard HPV testing method in head and neck cancers,[23] both in situ hybridization and PCR are commonly used.[12][24] A 2010 study has concluded that both have comparable performance for HPV detection, however it's important to use appropriate sensitivity controls.[25]


Risk factors are high number of sexual partners,[26][27][28] (25% increase >= 6 partners)[29] history of oral-genital sex,[27][28] (125% >= 4 partners)[29] history of anal–oral sex,[27] female partner had a history of either an abnormal Pap smear or a cervical dysplasia,[27][30] chronic periodontitis,[31][32] and, among men, decreasing age at first intercourse[26] and history of genital warts.[26]

A 2010 study concluded that current tobacco users with advanced HPV+ OSCC are at higher risk of disease recurrence compared with never-tobacco users.[33]

HPV vaccines have a theoretical potential to prevent oral HPV infection.[4]

A 2010 review study has found that HPV16 oral infection was rare (1.3%) among the 3,977 healthy subjects analyzed.[34]


Currently HPV+ OPC are treated similarly to stage-matched and site-matched unrelated OPC. However less intensive use of radiotherapy or chemotherapy, as well as specific therapy, is under research.[3][35]

It's hypothesized that HPV+ OPC patients benefit better from radiotherapy and concurrent cetuximab treatment than HPV- OPC patients receiving the same treatment.[36]


Tumor HPV status is strongly associated with positive therapeutic response and survival compared with HPV-negative OPC.[37][38][39] A possible explanation is "the lower probability of occurrence of 11q13 gene amplification, which is considered to be a factor underlying faster and more frequent recurrence of the disease"[6] Presence of TP53 mutations, a marker for HPV- OPC, is associated with worse prognosis.[4]

High grade of p16 staining is thought to be better than HPV PCR analysis in predicting radiotherapy response.[24]


HPV+ OPC patients tend to be younger than HPV- patients.[40] Currently in the US there is a growing incidence of HPV associated oropharyngeal cancers,[41][42][43] perhaps as a result of changing sexual behaviors.[44][45] Tonsil and oropharyngeal cancers increased in male predominance between 1975 and 2004, despite reductions in smoking.[46] The decline in smoking may be linked to the decreasing proportion of HPV negative cancers, while changes in sexual activity may be reflected in increasing proportion of HPV positive cancers.[47] Recently, in the US, HPV associated OPC represent about 60% of OPC cases[37][48][49] compared with 40% in the previous decade.[49] By 2007, in the US, incidence of general OPC, including non-HPV associated, is 3.9 cases per 100,000 males/year and 1.9 per 100,000 all-sexes/year.[50]

The higher increase incidence of HPV associated OPC is also seen in other countries, like Sweden, with a 2007 incidence of over 80% for cancer in the tonsils,[51][52] Finland[53] and Czech Republic.[54]

In Australia incidence of HPV associated OPC is 1.56 cases per 100,000 males/year.[55]


In 1983, it was first suggested[5] that HPV might be the agent involved in the development of at least certain special types of oral cancers.[56] In 2007 the [4][57]


  1. ^ Westra, W. H. (2009). "The Changing Face of Head and Neck Cancer in the 21st Century: the Impact of HPV on the Epidemiology and Pathology of Oral Cancer". Head and Neck Pathology 3 (1): 78–81.  
  2. ^ Gillison, M. L.; Koch, W. M.; Capone, R. B.; Spafford, M.; Westra, W. H.; Wu, L.; Zahurak, M. L.; Daniel, R. W.; Viglione, M.; Symer, D. E.; Shah, K. V.; Sidransky, D. (May 2000). "Evidence for a causal association between human papillomavirus and a subset of head and neck cancers" (Free full text). Journal of the National Cancer Institute 92 (9): 709–720.  
  3. ^ a b Psyrri, A.; Gouveris, P.; Vermorken, J. B. (2009). "Human papillomavirus-related head and neck tumors: clinical and research implication". Current Opinion in Oncology 21 (3): 201–205.  
  4. ^ a b c d e f g Chaturvedi, Anil; Maura L. Gillison (March 4, 2010). "Human Papillomavirus and Head and Neck Cancer". In Andrew F. Olshan. Epidemiology, Pathogenesis, and Prevention of Head and Neck Cancer (1st ed.). New York: Springer.  
  5. ^ a b c d Mannarini, L.; Kratochvil, V.; Calabrese, L.; Gomes Silva, L.; Morbini, P.; Betka, J.; Benazzo, M. (2009). "Human Papilloma Virus (HPV) in head and neck region: review of literature". Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale 29 (3): 119–126.  
  6. ^ a b c d e Michl, P; Pazdera, J; Prochazka, M; Pink, R; Stosova, T (2010). "Human papillomavirus in the etiology of head and neck carcinomas" (PDF). Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 154 (1): 9–12.  
  7. ^ Vidal, L.; Gillison, M. (2008). "Human papillomavirus in HNSCC: recognition of a distinct disease type". Hematology/oncology clinics of North America 22 (6): 1125–1142, vii.  
  8. ^ Guan, X.; Sturgis, E.; Lei, D.; Liu, Z.; Dahlstrom, K.; Wei, Q.; Li, G. (2010). "Association of TGF-beta1 genetic variants with HPV16-positive oropharyngeal cancer".  
  9. ^ Frisch, M.; Biggar, R. (1999). "Aetiological parallel between tonsillar and anogenital squamous-cell carcinomas". The Lancet 354 (9188): 1442.  
  10. ^ Underbrink, M.; Hoskins, S.; Pou, A.; Albrecht, T. (2008). "Viral interaction: a possible contributing factor in head and neck cancer progression". Acta Oto-Laryngologica 128 (12): 1361–1369.  
  11. ^ Smeets, S.; Van Der Plas, M.; Schaaij-Visser, T.; Van Veen, E.; Van Meerloo, J.; Braakhuis, B.; Steenbergen, R.; Brakenhoff, R. (2010). "Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways". International Journal of Cancer. Journal International Du Cancer 128 (7): n/a.  
  12. ^ a b Marur, S.; D'souza, G.; Westra, W. H.; Forastiere, A. A. (2010). "HPV-associated head and neck cancer: a virus-related cancer epidemic". The Lancet Oncology 11 (8): 781–789.  
  13. ^ Hunt, Jennifer L. (25 February 2010). "Molecular Assessment of HPV in Patients with Head and Neck Tumors" (PDF). Retrieved 13 May 2010. 
  14. ^ Salem, A. (2010). "Dismissing links between HPV and aggressive tongue cancer in young patients". Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 21 (1): 13–17.  
  15. ^ Klussmann, J.; Mooren, J.; Lehnen, M.; Claessen, S.; Stenner, M.; Huebbers, C.; Weissenborn, S.; Wedemeyer, I.; Preuss, S.; Straetmans, J. M. J. A. A.; Manni, J. J.; Hopman, A. H. N.; Speel, E. -J. M. (Mar 2009). "Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications".  
  16. ^ Lohavanichbutr, P.; Houck, J.; Fan, W.; Yueh, B.; Mendez, E.; Futran, N.; Doody, D.; Upton, M.; Farwell, D.; Schwartz, S. M.; Zhao, L. P.; Chen, C. (Feb 2009). "Genome-wide gene expression profiles of HPV-positive and HPV-negative oropharyngeal cancer: potential implications for treatment choices". Archives of Otolaryngology—Head & Neck Surgery 135 (2): 180–188.  
  17. ^ Schlecht, N.; Burk, R.; Adrien, L.; Dunne, A.; Kawachi, N.; Sarta, C.; Chen, Q.; Brandwein-Gensler, M.; Prystowsky, M.; Childs, G.; Smith, R. V.; Belbin, T. J. (Nov 2007). "Gene expression profiles in HPV-infected head and neck cancer". The Journal of pathology 213 (3): 283–293.  
  18. ^ Weinberger, P.; Yu, Z.; Kountourakis, P.; Sasaki, C.; Haffty, B.; Kowalski, D.; Merkley, M.; Rimm, D.; Camp, R.; Psyrri, A. (Sep 2009). "Defining molecular phenotypes of human papillomavirus-associated oropharyngeal squamous cell carcinoma: Validation of three-class hypothesis". Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 141 (3): 382–389.e1.  
  19. ^ Martinez, I.; Wang, J.; Hobson, K.; Ferris, R.; Khan, S. (Jan 2007). "Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas". European journal of cancer (Oxford, England : 1990) 43 (2): 415–432.  
  20. ^ Jung, A.; Briolat, J.; Millon, R.; De Reyniès, A.; Rickman, D.; Thomas, E.; Abecassis, J.; Clavel, C.; Wasylyk, B. (2009). "Biological and clinical relevance of transcriptionnally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma". International Journal of Cancer. Journal International Du Cancer 126 (8): 1882–1894.  
  21. ^ Chernock, R. D.; El-mofty, S. K.; Thorstad, W. L.; Parvin, C. A.; Lewis, J. S. (2009). "HPV-Related Nonkeratinizing Squamous Cell Carcinoma of the Oropharynx: Utility of Microscopic Features in Predicting Patient Outcome". Head and Neck Pathology 3 (3): 186–194.  
  22. ^ Elmofty, S.; Patil, S. (2006). "Human papillomavirus (HPV)-related oropharyngeal nonkeratinizing squamous cell carcinoma: Characterization of a distinct phenotype". Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 101 (3): 339–345.  
  23. ^ Robinson, M.; Sloan, P.; Shaw, R. (2010). "Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus testing.". Oral oncology 46 (7): 492–496.  
  24. ^ a b Munck-Wikland, Eva; Hammarstedt, Lalle; Dahlstrand, Hanna (2010). "Role of Human Papillomavirus in Tonsillar Cancer". In M. A. Hayat. Methods of Cancer Diagnosis, Therapy, and Prognosis 7. Springer. pp. 271–283.  
  25. ^ Agoston, E. .; Robinson, S. .; Mehra, K. .; Birch, C. .; Semmel, D. .; Mirkovic, J. .; Haddad, R. .; Posner, M. .; Kindelberger, D. .; Krane, J. F.; Brodsky, J.; Crum, C. P. (2010). "Polymerase chain reaction detection of HPV in squamous carcinoma of the oropharynx". American journal of clinical pathology 134 (1): 36–41.  
  26. ^ a b c Schwartz, S. M.; Daling, J. R.; Doody, D. R.; Wipf, G. C.; Carter, J. J.; Madeleine, M. M.; Mao, E. J.; Fitzgibbons, E. D.; Huang, S.; Beckmann, A. M.; McDougall, J. K.; Galloway, D. A. (1998). "Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection". Journal of the National Cancer Institute 90 (21): 1626–1636.  
  27. ^ a b c d Smith, E.; Ritchie, J.; Summersgill, K.; Klussmann, J.; Lee, J.; Wang, D.; Haugen, T.; Turek, L. (Feb 2004). "Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers". International Journal of Cancer. Journal International Du Cancer 108 (5): 766–772.  
  28. ^ a b D'Souza, G.; Kreimer, A.; Viscidi, R.; Pawlita, M.; Fakhry, C.; Koch, W.; Westra, W.; Gillison, M. (May 2007). "Case-control study of human papillomavirus and oropharyngeal cancer". The New England Journal of Medicine 356 (19): 1944–1956.  
  29. ^ a b Heck, J.; Berthiller, J.; Vaccarella, S.; Winn, D.; Smith, E.; Shan'Gina, O.; Schwartz, S.; Purdue, M.; Pilarska, A.; Eluf-Neto, J.; Menezes, A.; McClean, M. D.; Matos, E.; Koifman, S.; Kelsey, K. T.; Herrero, R.; Hayes, R. B.; Franceschi, S.; Wünsch-Filho, V.; Fernández, L.; Daudt, A. W.; Curado, M. P.; Chen, C.; Castellsagué, X.; Ferro, G.; Brennan, P.; Boffetta, P.; Hashibe, M. (2009). "Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium". International Journal of Epidemiology 39 (1): 166–181.  
  30. ^ Hemminki, K.; Dong, C.; Frisch, M. (Dec 2000). "Tonsillar and other upper aerodigestive tract cancers among cervical cancer patients and their husbands". European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 9 (6): 433–437.  
  31. ^ Tezal, M.; Sullivan Nasca, M.; Stoler, D.; Melendy, T.; Hyland, A.; Smaldino, P.; Rigual, N.; Loree, T. (Apr 2009). "Chronic periodontitis-human papillomavirus synergy in base of tongue cancers". Archives of Otolaryngology—Head & Neck Surgery 135 (4): 391–396.  
  32. ^ Tezal, M.; Sullivan, M.; Hyland, A.; Marshall, J.; Stoler, D.; Reid, M.; Loree, T.; Rigual, N.; Merzianu, M.; Hauck, L.; Lillis, C.; Wactawski-Wende, J.; Scannapieco, F. A. (2009). "Chronic periodontitis and the incidence of head and neck squamous cell carcinoma". Cancer Epidemiology, Biomarkers & Prevention 18 (9): 2406–2412.  
  33. ^ Maxwell, J. H.; Kumar, B.; Feng, F. Y.; Worden, F. P.; Lee, J. S.; Eisbruch, A.; Wolf, G. T.; Prince, M. E.; Moyer, J. S.; Teknos, T. N.; Chepeha, D. B.; McHugh, J. B.; Urba, S. G.; Stoerker, J.; Walline, H. M.; Kurnit, D. M.; Cordell, K. G.; Davis, S. J.; Ward, P. D.; Bradford, C. R.; Carey, T. E. (2010). "Tobacco Use in Human Papillomavirus-Positive Advanced Oropharynx Cancer Patients Related to Increased Risk of Distant Metastases and Tumor Recurrence". Clinical Cancer Research 16 (4): 1226–1235.  
  34. ^ Kreimer, A.; Bhatia, R.; Messeguer, A.; González, P.; Herrero, R.; Giuliano, A. (2010). "Oral Human Papillomavirus in Healthy Individuals: A Systematic Review of the Literature". Sexually transmitted diseases 37 (6): 386–391.  
  35. ^ Lassen, P. (2010). "The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome". Radiotherapy and Oncology 95 (3): 371–380.  
  36. ^ Eriksen, J. G.; Lassen, P.; Overgaard, J. (2010). "Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab?". The Lancet Oncology 11 (4): 312–3.  
  37. ^ a b Fakhry, C.; Westra, W.; Li, S.; Cmelak, A.; Ridge, J.; Pinto, H.; Forastiere, A.; Gillison, M. (Feb 2008). "Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial" (Free full text). Journal of the National Cancer Institute 100 (4): 261–269.  
  38. ^ de Jong, M. C.; Pramana, J.; Knegjens, J. L.; Balm, A. J. M.; Van Den Brekel, M. W. M.; Hauptmann, M.; Begg, A. C.; Rasch, C. R. N. (24 March 2010). "HPV and high-risk gene expression profiles predict response to chemoradiotherapy in head and neck cancer, independent of clinical factors". Radiotherapy and Oncology 95 (3): 365–370.  
  39. ^ Ang, K. K.; Harris, J.; Wheeler, R.; Weber, R.; Rosenthal, D. I.; Nguyen-Tân, P. F.; Westra, W. H.; Chung, C. H.; Jordan, R. C.; Lu, C.; Kim, H.; Axelrod, R.; Silverman, C. C.; Redmond, K. P.; Gillison, M. L. (2010). "Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer". New England Journal of Medicine 363 (1): 24–35.  
  40. ^ Lajer, C. B.; Buchwald, C. V. (2010). "The role of human papillomavirus in head and neck cancer". APMIS 118 (6–7): 510–9.  
  41. ^ Sturgis, E.; Cinciripini, P. (Oct 2007). "Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers?". Cancer 110 (7): 1429–1435.  
  42. ^ Ernster, J.; Sciotto, C.; O'Brien, M.; Finch, J.; Robinson, L.; Willson, T.; Mathews, M. (Dec 2007). "Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus". The Laryngoscope 117 (12): 2115–2128.  
  43. ^ Hammarstedt, L.; Lindquist, D.; Dahlstrand, H.; Romanitan, M.; Dahlgren, L.; Joneberg, J.; Creson, N.; Lindholm, J.; Ye, W.; Dalianis, T.; Munck-Wikland, E. (Dec 2006). "Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer". International Journal of Cancer. Journal International Du Cancer 119 (11): 2620–2623.  
  44. ^ Chaturvedi, A.; Engels, E.; Anderson, W.; Gillison, M. (Feb 2008). "Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States". Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26 (4): 612–619.  
  45. ^ Nguyen, N. P.; Chi, A.; Nguyen, L. M.; Ly, B. H.; Karlsson, U.; Vinh-Hung, V. (2009). "Human papillomavirus-associated oropharyngeal cancer: a new clinical entity". QJM 103 (4): 229–236.  
  46. ^ Cook, M.; Dawsey, S.; Freedman, N.; Inskip, P.; Wichner, S.; Quraishi, S.; Devesa, S.; McGlynn, K. (2009). "Sex disparities in cancer incidence by time period and age". Cancer Epidemiology, Biomarkers & Prevention 18 (4): 1174–1182.  
  47. ^ Chaturvedi, A. K.; Engels, E. A.; Pfeiffer, R. M.; Hernandez, B. Y.; Xiao, W.; Kim, E.; Jiang, B.; Goodman, M. T.; Sibug-Saber, M.; Cozen, W.; Liu, L.; Lynch, C. F.; Wentzensen, N.; Jordan, R. C.; Altekruse, S.; Anderson, W. F.; Rosenberg, P. S.; Gillison, M. L. (2011). "Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States". Journal of Clinical Oncology 29 (32): 4294–4301.  
  48. ^ Adelstein, D. J.; Cristina P. Rodriguez (February 3, 2010). "Human Papillomavirus: Changing Paradigms in Oropharyngeal Cancer". Current Oncology Reports (Current Medicine Group LLC) 12 (2): 115–120.  
  49. ^ a b "Oropharyngeal carcinoma related to human papillomavirus". BMJ 340: c1439. 2010.  
  50. ^ "Cancer of the Oral Cavity and Pharynx by Subsite". SEER Cancer Statistics Review 1975-2007. Surveillance, Epidemiology and End Results (SEER) Program. 15 April 2010. Retrieved 18 April 2010. 
  51. ^ Näsman, A.; Attner, P.; Hammarstedt, L.; Du, J.; Eriksson, M.; Giraud, G.; Ahrlund-Richter, S.; Marklund, L.; Romanitan, M.; Lindquist, D.; Ramqvist, T. R.; Lindholm, J.; Sparén, P. R.; Ye, W.; Dahlstrand, H.; Munck-Wikland, E.; Dalianis, T. (Jul 2009). "Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma?". International Journal of Cancer. Journal International Du Cancer 125 (2): 362–366.  
  52. ^ Hammarstedt, Lalle (2008), Tonsillar Cancer - Incidence, Prevalence of HPV and Survival (PDF), Stockholm,  
  53. ^ Syrjänen, S. (2004). "HPV infections and tonsillar carcinoma". Journal of Clinical Pathology 57 (5): 449–455.  
  54. ^ Tachezy, R. "HPV and other risk factors of oral cavity/oropharyngeal cancer in the Czech Republic". Oral Diseases 11 (3): 181–185.  
  55. ^ Hong, A. M.; Grulich, A. E.; Jones, D.; Lee, C. S.; Garland, S. M.; Dobbins, T. A.; Clark, J. R.; Harnett, G. B.; Milross, C. G.; O'Brien, C. J.; Rose, B. R. (2010). "Squamous cell carcinoma of the oropharynx in Australian males induced by human papillomavirus vaccine targets". Vaccine 28 (19): 3269–3272.  
  56. ^ Syrjänen, K.; Syrjänen, S.; Lamberg, M.; Pyrhönen, S.; Nuutinen, J. (1983). "Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis". International journal of oral surgery 12 (6): 418–424.  
  57. ^ International Agency for Research on Cancer (2007) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. vol 90: Human Papillomaviruses

Further reading

  • Chaturvedi, Anil; Maura L. Gillison (March 4, 2010). "Human Papillomavirus and Head and Neck Cancer". In Andrew F. Olshan. Epidemiology, Pathogenesis, and Prevention of Head and Neck Cancer (1st ed.). New York: Springer.  
  • Ramqvist T, Dalianis T. (2010) Oropharyngeal cancer epidemic and human papillomavirus. Emerg Infect Dis.

External links

  • Is Oral Sex Safe? (Television production). England: BBC Three. 10 January 2011. 
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.